Inflammatory Mediators in Early Sepsis

Last updated: June 4, 2021
Sponsor: University Hospital Tuebingen
Overall Status: Active - Recruiting

Phase

N/A

Condition

Inflammation

Treatment

N/A

Clinical Study ID

NCT02692118
AnaTubingen
  • Ages 18-85
  • All Genders

Study Summary

Sepsis is still a challenge for clinicians since the detailed pathomechanism are still unknown and until now early markers for sepsis are not defined yet. Immunological pathways and new mediators defined in animal models are not yet investigated in patients with sepsis. Therefore the investigators will measure new mediators in patients with septic shock.

Eligibility Criteria

Inclusion

Inclusion Criteria:

  • Septic Shock

Exclusion

Exclusion Criteria:

  • Age < 18 > 85
  • no consent of caregiver
  • Trauma patients
  • Burn patients
  • Immunosuppression
  • Pregnancy
  • HIV- hepatitis infection

Study Design

Total Participants: 60
Study Start date:
December 01, 2016
Estimated Completion Date:
September 30, 2022

Study Description

Semaphorins 1 to 7 will be determined in Blood of patients with early septic shock. Concentration will be compared with blood concentration of postoperative patients suffering systemic inflammatory response syndrome (SIRS).

Connect with a study center

  • University Hospital Tuebingen

    Tuebingen, 72076
    Germany

    Active - Recruiting

Not the study for you?

Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.